SCHEMBL23168969

SCHEMBL23168969

Nc1cc(Cl)c(Oc2cnc(=O)n(Cc3ccc(F)cc3)c2)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ THRB P10828 2/20 0.38
▸ THRA P10827 1/20 0.38
▸ HTT P42858 2/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ MITF O75030 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ USP2 O75604 3/20 0.35
▸ CYP1A2 P05177 3/20 0.35
▸ CYP3A4 P08684 3/20 0.35
▸ TSHR P16473 3/20 0.35
▸ CYP2C19 P33261 3/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ NPBWR1 P48145 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23152133 0.88 NPBWR1 (0.40) NPBWR1MAPK14
SCHEMBL29821664 0.85 SOS1 (0.43) MAPTLMNATHRBTHRAHTT
SCHEMBL23168940 0.82 MAPT (0.40) MAPTLMNATHRBTHRABACE1
SCHEMBL23168968 0.76 THRA (0.47) THRBTHRACYP2C9
SCHEMBL29822156 0.73 ALOX12 (0.42) MAPTTHRBHTTRAB9AALDH1A1
SCHEMBL31356395 0.73 MAPT (0.40) MAPTHTTCYP1A2CYP3A4CYP2C19
SCHEMBL23168951 0.73 MAPT (0.40) MAPTHTTCYP1A2CYP3A4CYP2C19
SCHEMBL24449327 0.71 NPBWR1 (0.36) MAPTNPBWR1
SCHEMBL23168775 0.71 MAPT (0.43) MAPTLMNAHTTNPSR1CYP1A2
SCHEMBL23168931 0.71 NPBWR1 (0.46) MAPTLMNANPBWR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-05-05 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
EP-4036090-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-08-03 — — EP disclosed
WO-2021057791-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF 广东东阳光药业有限公司 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF THRB, TSHR, THRA MAPT 1873/4885LMNA 3346/4885THRB 1/4885
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof THRB, TSHR, THRA MAPT 2264/4885LMNA 1606/4885THRB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback